Cantor Fitzgerald Increases Earnings Estimates for Pharvaris

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share estimate for Pharvaris to ($2.87) from a previous forecast of ($3.41). They maintain an "Overweight" rating with a price target of $25.00.
• Pharvaris reported a quarterly earnings result of ($0.94) EPS, missing expectations by ($0.07).
• Five investment analysts currently rate Pharvaris with a "buy" recommendation, leading to an average target price of $35.60 for the stock.

Pharvaris N.V. (NASDAQ:PHVS - Free Report) - Analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Pharvaris in a report issued on Wednesday, August 13th. Cantor Fitzgerald analyst S. Seedhouse now expects that the company will post earnings per share of ($2.87) for the year, up from their previous forecast of ($3.41). Cantor Fitzgerald has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share. Cantor Fitzgerald also issued estimates for Pharvaris' FY2026 earnings at ($2.72) EPS.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.07).

Several other research firms have also recently issued reports on PHVS. Guggenheim began coverage on Pharvaris in a research note on Wednesday, June 11th. They set a "buy" rating and a $32.00 target price for the company. Wedbush reaffirmed an "outperform" rating and issued a $27.00 price objective on shares of Pharvaris in a research note on Thursday, June 5th. Finally, JMP Securities dropped their price objective on Pharvaris from $55.00 to $52.00 and set a "market outperform" rating for the company in a research note on Wednesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $35.60.

Pharvaris Trading Down 1.3%

PHVS stock traded down $0.30 during midday trading on Friday, hitting $22.70. 2,963 shares of the company's stock were exchanged, compared to its average volume of 77,415. The business has a 50-day simple moving average of $19.60 and a two-hundred day simple moving average of $17.21. The stock has a market capitalization of $1.19 billion, a PE ratio of -6.75 and a beta of -2.81. Pharvaris has a 1-year low of $11.51 and a 1-year high of $26.33.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PHVS. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in Pharvaris in the second quarter valued at $57,000. JPMorgan Chase & Co. boosted its holdings in Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after purchasing an additional 2,847 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Pharvaris in the fourth quarter valued at $64,000. Point72 Asset Management L.P. purchased a new position in Pharvaris in the fourth quarter valued at $152,000. Finally, Legal & General Group Plc boosted its holdings in Pharvaris by 11.2% in the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock valued at $189,000 after purchasing an additional 994 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.